Evidence map›Paper›PMID 35273094›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022

Harun Ilhan, Markus Kroenke, Alexander Wurzer, Marcus Unterrainer, Matthias Heck, Claus Belka, Karina Knorr, Thomas Langbein, Isabel Rauscher, Nina-Sophie Schmidt-Hegemann and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Harun IlhanDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany; harun.ilhan@med.uni-muenchen.de.
Markus KroenkeDepartment of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
Alexander WurzerChair of Pharmaceutical Radiochemistry, Technical University of Munich, Garching, Germany.
Marcus UnterrainerDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Matthias HeckDepartment of Urology, Technical University of Munich, Munich, Germany.
Claus BelkaDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; and.
Karina KnorrDepartment of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
Thomas LangbeinDepartment of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
Isabel RauscherDepartment of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
Nina-Sophie Schmidt-HegemannDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; and.
Kilian SchillerDepartment of Radiation Oncology, School of Medicine, Technical University of Munich, Munich, Germany.
Peter BartensteinDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Hans-Jürgen WesterChair of Pharmaceutical Radiochemistry, Technical University of Munich, Garching, Germany.
Matthias EiberDepartment of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
Technical University of Munich · DELMU Klinikum · DELudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This bicentric, retrospective analysis investigated the efficacy of PET/CT with a novel theranostic prostate-specific membrane antigen (PSMA)--targeting ligand,

Indexed as

Prostatic NeoplasmsAndrogen AntagonistsGallium RadioisotopesHumansLymphatic MetastasisMaleNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyProstate-Specific AntigenRetrospective StudiesAndrogen AntagonistsGallium RadioisotopesProstate-Specific AntigenBCRbiochemical recurrencePET imagingprostate-specific membrane antigenPSMAradiation therapy

Identifiers

PMID35273094
PMCPMC9364349
OpenAlexW4221086565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.